Canadian Psychedelics Company Reduces Manufacturing Time Of MDMA By Two Thirds
Nirvana Life Sciences Inc. (CSE: NIRV) announced that it has engineered a method that reduces the manufacturing time of MDMA by two thirds.
Psychedelics Company Nabs Health Canada Construction Permit, Find Out How They Got It
Canadian life sciences company Nirvana Life Sciences Inc. (CSE: NIRV), focused on research & development of non-addictive pain management and relapse prevention products for pain and addictions, has been granted approval to build its R&D facility in Vancouver by Canada’s governmental department of Health.
Psyched: Christie’s Launches NFT Collection Supporting Psychedelic Science, Origin’s Listing On CSE Gives Retail Investors Access To Private Companies
The world of psychedelics is getting a crossover with another category in the millennial catalog of trendy investments: NFTs.
Addiction Relapse Prevention: Nirvana Pre-Clinical Study Suggests Psilocybin Could Help Heroin Addiction
Nirvana Life Sciences Inc. (CSE: NIRV) is a Canadian-based life sciences company that develops novel therapeutic products derived from psychedelics to produce non-addictive solutions for opioid addiction treatment and ongoing pain management.
Nirvana has recently joined forces with Integrative Therapy Discovery (ITD) Labs of Italy.